Results 281 to 290 of about 2,143,328 (347)

Analysis of 4616 clinical trial initial submissions received by the Medicines and Healthcare products Regulatory Agency between February 2019 and October 2023

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse clinical trial initial submissions received by the MHRA between February 2019 and October 2023. Methods Data on submissions were extracted from the clinical trials unit data bank. The primary end‐point was the type of clinical trial initial submissions.
Andrea Manfrin   +4 more
wiley   +1 more source

Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit   +6 more
wiley   +1 more source

Epilepsy and the Adolescent

open access: yesJournal of the Royal College of Physicians of London, 2000
openaire   +3 more sources

Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To characterize the pharmacokinetics (PK) and PK/pharmacodynamics (PD) regarding glycosylated haemoglobin (HbA1c) lowering using the paediatric data from DINAMO and to assess differences compared with adults. Methods Population PK and PK/PD models previously developed for empagliflozin in adults and adolescents were re‐estimated in a Bayesian ...
Juliane Rascher   +7 more
wiley   +1 more source

Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims There is a potential risk of systemic side‐effects with the use of potent corticosteroids, such as clobetasol propionate (CP). This concern is of particular interest in paediatric patients. The aim of this study was to develop and verify a physiologically based pharmacokinetic (PBPK) model to describe the local and systemic exposure to CP
Janna K. Duong   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy